Search results for "CEP"

showing 10 items of 17875 documents

Heat shock protein (Hsp) regulation by muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus.

2018

The cholinergic system plays a crucial role in modulating in the central nervous system physiological responses such as neurogenesis, neuronal differentiation, synaptic plasticity, and neuroprotection. In a recent study, we showed that Oxotremorine-M, a non-selective muscarinic acetylcholine receptor agonist, is able to transactivate the fibroblast growth factor receptor and to produce a significant increase in the hippocampal primary neurite outgrowth. In the present study we aimed to explore in the rat hippocampus the possible effect of acute or chronic treatment with Oxotremorine-M on some heat shock proteins (Hsp60, Hsp70, Hsp90) and on activation of related transcription factor heat sh…

0301 basic medicineAgonistMalemedicine.medical_specialtymedicine.drug_classPhysiologyClinical BiochemistryNeuronal OutgrowthScopolamineheat shock proteinHsp90NeuroprotectionHippocampusHsp7003 medical and health sciencesmuscarinic receptor0302 clinical medicineHeat Shock Transcription FactorsHeat shock proteinInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineAnimalsRats WistarHSF1Heat-Shock ProteinsNeuronsNeuronal PlasticityChemistryOxotremorineNeurodegenerative DiseasesCell BiologyReceptors Fibroblast Growth FactorReceptors MuscarinicHsp70Rats030104 developmental biologyEndocrinologyheat shock factor 1HSP60030217 neurology & neurosurgerymedicine.drugSignal TransductionJournal of cellular physiology
researchProduct

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Can…

2017

AbstractSomatic mutations of the Estrogen Receptor α (ERα) occur with an up to 40% incidence in ER sensitive breast cancer (BC) patients undergoing prolonged endocrine treatments. These polymorphisms are implicated in acquired resistance, disease relapse, and increased mortality rates, hence representing a current major clinical challenge. Here, multi-microseconds (12.5 µs) molecular dynamics simulations revealed that recurrent ERα polymorphisms (i. e. L536Q, Y537S, Y537N, D538G) (mERα) are constitutively active in their apo form and that they prompt the selection of an agonist (active)-like conformation even upon antagonists binding. Interestingly, our simulations rationalize, for the firs…

0301 basic medicineAgonistModels MolecularBreast cancerComputational chemistryMolecular dynamicsSomatic cellmedicine.drug_classlcsh:MedicineEstrogen receptorBreast Neoplasms-Molecular Dynamics SimulationPolymorphism Single NucleotideArticleProtein Structure SecondaryEstrogen Receptor Antagonists03 medical and health sciences0302 clinical medicineBreast cancermedicineEndocrine systemHumanslcsh:ScienceMultidisciplinarybusiness.industrylcsh:REstrogen Receptor alphamedicine.diseaseEstrogen Receptor Antagonist030104 developmental biologySelective estrogen receptor modulator030220 oncology & carcinogenesisCancer researchlcsh:QFemaleEstrogen Receptor AntagonistsbusinessEstrogen receptor alphaBreast NeoplasmHuman
researchProduct

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

2017

The mechanisms leading to improvement of overactive bladder syndrome upon treatment with a β3-adrenoceptor agonist remain controversial. New research points to a role of inhibition of neuronal acetylcholine release. Whether this occurs by a direct effect on prejunctional β3-adrenoceptors or indirectly by formation of adenosine and activation of A1 adenosine receptors is being discussed.

0301 basic medicineAgonistSmooth muscle relaxationmedicine.medical_specialtyUrinary bladderPhysiologymedicine.drug_classbusiness.industryOveractive bladder syndromeAdenosine receptorAdenosine03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureEndocrinologyInternal medicinemedicineβ3 adrenoceptorbusiness030217 neurology & neurosurgeryAcetylcholinemedicine.drugAmerican Journal of Physiology-Renal Physiology
researchProduct

Taurine potentiates the anticonvulsive effect of the GABAAagonist muscimol and pentobarbital in the immature mouse hippocampus

2019

Objective The high incidence of epileptic seizures in neonates and their frequent refractoriness to pharmacologic therapies require identification of new therapeutical options. Therefore, we investigated whether the modulatory effect of taurine on γ-aminobutyric acid (GABA)A receptors can enhance the anticonvulsive potential of the GABAA receptor agonist muscimol and of the barbiturate pentobarbital. Methods We performed field potential recordings in in toto hippocampus preparations of immature (postnatal days 4-7) C57Bl/6 mouse pups. Spontaneous epileptiform activity was induced by the continuous presence of the potassium channel blocker 4-aminopyridine and the glycinergic antagonist stryc…

0301 basic medicineAgonistTaurinePentobarbitalTaurine bindingmedicine.drug_classGABAA receptorPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinenervous systemNeurologychemistryMuscimolBarbituratemedicineNeurology (clinical)Glycine receptor030217 neurology & neurosurgerymedicine.drugEpilepsia
researchProduct

GABAA receptors in the ventral tegmental area control the outcome of a social competition in rats

2018

Social dominance can be attained through social competitions. Recent work in both humans and rodents has identified trait anxiety as a crucial predictor of social competitiveness. In addition, the anxiolytic GABAA positive modulator, diazepam, injected either systemically or into the ventral tegmental area (VTA) was shown to increase social dominance. Here, we investigated the impact of pharmacologically targeting GABAA receptors in the VTA for the outcome of a social competition between two unfamiliar male rats, one of them infused with vehicle and the other one with the drug under study. We show that infusion of the GABAA receptor agonist, muscimol, reduced anxiety-like behaviors and enha…

0301 basic medicineAgonistZolpidemmedicine.drug_classgamma-Aminobutyric acid03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicinemedicinePharmacologyBenzodiazepineGABAA receptorbusiness.industrymusculoskeletal neural and ocular physiologyBicucullineVentral tegmental area030104 developmental biologymedicine.anatomical_structurenervous systemMuscimolchemistrybusinessNeurosciencepsychological phenomena and processes030217 neurology & neurosurgerymedicine.drugNeuropharmacology
researchProduct

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

2021

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic contr…

0301 basic medicineAgonistendocrine systemmedicine.drug_classDiseasePharmacologyCardiovascular SystemGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineGlucagon-Like Peptide 1Diabetes mellitusMedicineHumansHypoglycemic AgentsReceptorGlucagon-like peptide 1 receptorPharmacologyKidneybusiness.industrydigestive oral and skin physiologyType 2 Diabetes Mellitusmedicine.diseaseGlucagon-like peptide-1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Cardiovascular Diseasesbusinesshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryBritish journal of pharmacology
researchProduct

β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project

2016

β3-Adrenoceptor agonists were originally considered as a promising drug class for the treatment of obesity and/or type 2 diabetes. When these development efforts failed, they were repositioned for the treatment of the overactive bladder syndrome. Based on the example of the β3-adrenoceptor agonist mirabegron, but also taking into consideration evidence obtained with ritobegron and solabegron, we discuss challenges facing a translational pharmacology program accompanying clinical drug development for a first-in-class molecule. Challenges included generic ones such as ligand selectivity, species differences and drug target gene polymorphisms. Challenges that are more specific included changin…

0301 basic medicineAgonistmedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor AgonistsAdrenergic beta-3 Receptor AgonistsPharmacologyLigandsAntibodiesTranslational Research Biomedical03 medical and health sciencesSolabegronmedicineAnimalsHumansPharmacology (medical)PharmacologyUrinary Bladder Overactivebusiness.industryDrug RepositioningSyndromeOveractive bladder syndromeDrug repositioning030104 developmental biologyDrug classDrug developmentReceptors Adrenergic beta-3Adrenergic beta-3 Receptor AntagonistsbusinessMirabegronmedicine.drugPharmacology & Therapeutics
researchProduct

TRAIL–NP hybrids for cancer therapy: a review

2017

IF 7.367; International audience; Cancer is a worldwide health problem. It is now considered as a leading cause of morbidity and mortality in developed countries. In the last few decades, considerable progress has been made in anti-cancer therapies, allowing the cure of patients suffering from this disease, or at least helping to prolong their lives. Several cancers, such as those of the lung and pancreas, are still devastating in the absence of therapeutic options. In the early 90s, TRAIL (Tumor Necrosis Factor-related apoptosis-inducing ligand), a cytokine belonging to the TNF superfamily, attracted major interest in oncology owing to its selective anti-tumor properties. Clinical trials u…

0301 basic medicineAgonistmedicine.drug_classmedicine.medical_treatmentApoptosis[SDV.CAN]Life Sciences [q-bio]/Cancer02 engineering and technologyDiseaseCD8-Positive T-Lymphocytes[ SDV.CAN ] Life Sciences [q-bio]/CancerTNF-Related Apoptosis-Inducing Ligand03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerNeoplasmsHumansMedicineGeneral Materials Science[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyAnti-cancer therapiesReceptor[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyComputingMilieux_MISCELLANEOUSbiologybusiness.industryCancer021001 nanoscience & nanotechnologymedicine.disease3. Good healthKiller Cells NaturalReceptors TNF-Related Apoptosis-Inducing LigandAntitumoral properties030104 developmental biologyCytokineImmunologyCancer researchbiology.proteinNanoparticlesTumor necrosis factor alphaAntibody0210 nano-technologybusinessCD8
researchProduct

5-HT1A Receptor Function Makes Wound Healing a Happier Process

2018

Skin wound healing is a multistage phenomenon that is regulated by cell–cell interplay and various factors. Endogenous serotonin is an important neurotransmitter and cytokine. Its interaction with the serotonin 1A receptor (5-HTR1A) delivers downstream cellular effects. The role of serotonin (5-hydroxytryptamine, 5-HT) and the 5-HT1A receptor has been established in the regeneration of tissues such as the liver and spinal motor neurons, prompting the investigation of the role of 5-HT1A receptor in skin healing. This study assessed the role of 5-HT1A receptor in excisional wound healing by employing an excisional punch biopsy model on 5-Ht1a receptor knockout mice. Post-harvest analysis reve…

0301 basic medicineAgonistmedicine.drug_classmedicine.medical_treatmentwound healingPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineskin regenerationmedicine5-HT1A receptorPharmacology (medical)NeurotransmitterReceptor5-Ht1a receptor knockout mice modelOriginal ResearchPharmacologySkin repairintegumentary systembusiness.industrylcsh:RM1-950serotonin3. Good healthlcsh:Therapeutics. Pharmacology030104 developmental biologyCytokinenervous systemchemistry030220 oncology & carcinogenesisKnockout mouse5-HT1A receptorWound healingbusinessFrontiers in Pharmacology
researchProduct

β(3)‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

2019

β(3)‐Adrenoceptor agonists are used in the treatment of overactive bladder syndrome. Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle cells is mediated mainly via β(3)‐adrenoceptors, the plasma concentrations of the therapeutic dose of mirabegron, the only clinically approved β(3)‐adrenoceptor agonist, are considerably lower than the EC(50) for causing direct relaxation of human detrusor, suggesting a mechanism of action other than direct relaxation of detrusor smooth muscle. However, the site and mechanism of action of β(3)‐adrenoceptor agonists in the bladder have not been firmly established. Postulated mechanisms include prejunctional suppression o…

0301 basic medicineAgonistmedicine.medical_specialtyAdrenergic receptormedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor Agonistsurologic and male genital diseasesThemed Section: Review Articles03 medical and health sciences0302 clinical medicineTherapeutic indexDesensitization (telecommunications)Internal medicineMedicineAnimalsHumansPharmacologyUrinary bladderRelaxation (psychology)business.industry030104 developmental biologymedicine.anatomical_structureEndocrinologyMechanism of actionReceptors Adrenergic beta-3medicine.symptombusinessMirabegron030217 neurology & neurosurgerymedicine.drug
researchProduct